Abstract:As a key mediator of chronic pain, neurotrophin nerve growth factor (NGF) binds to two neurotrophin receptors: p75 neurotrophin receptor (p75NTR) and tyrosine kinase receptor A (TrkA). The formation of the p75NTR-NGF-TrkA complex is implicated in the potentiation of chronic pain signals, making it an attractive target for therapeutic explorations. NGF analogues and monoclonal antibodies (mAbs) targeting NGF represent two distinct approaches in modulating the intricate signaling pathways involved in pain transduction mediated by the p75NTR-NGF-TrkA complex. While NGF analogues offer the advantage of tailored design to fine-tune neurotrophic responses, monoclonal antibodies provide a more systemic and comprehensive blockade of NGF, inhibiting its interactions with both p75NTR and TrkA receptors. However, the use of mAbs may pose challenges related to potential side effects and interference with the physiological functions of NGF. As a result, balancing the benefits and drawbacks of the two approaches is critical for advancing therapeutic strategies towards the alleviation of p75NTR-NGF-TrkA-mediated pain. In this study, therefore, a novel structural and biophysical approach was employed for the design of NGF analogues to suppress p75NTR-NGF-TrkA-related chronic pain signaling. Employing high-throughput structural modeling and biophysics-based intermolecular binding affinity calculations, this article for the first time puts forward a set of NGF analogues, including in particular NGF analogues with four site-specific mutations, for whose dimerizations the K d at 37 ◦C were reduced by three orders of magnitude (from 10-9 M to 10-6 M) compared to the K d at 37 ◦C for the dimerization of native NGFs. Overall, the integration of structural and biophysical perspectives enhances our understanding of the rational design of NGF analogues as promising candidates for the development of NGF-targeted analgesic therapies, which balances the benefits and drawbacks of anti-NGF antibodies and NGF analogues for advancing therapeutic strategies towards the alleviation of p75NTR-NGF-TrkA-mediated pain.

A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties

A Centipede Toxin Causes Rapid Desensitization of Nociceptor TRPV1 Ion Channel.

Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

Dual Antagonism of Α9α10 Nachr and GABAB Receptor-Coupled CaV2.2 Channels by an Analgesic Αo-Conotoxin Analogue.

Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog

Design, Synthesis, and In Vitro Characterization of Proteolytically-Stable Opioid-Neurotensin Hybrid Peptidomimetics

Cell-penetrating pepducins targeting the neurotensin receptor type 1 relieve pain

De Novo Design of Peptidic Positive Allosteric Modulators Targeting TRPV1 with Analgesic Effects

Design, Synthesis and Mechanism of Action of Novel Μ-Conotoxin KIIIA Analogs for Inhibition of the Voltage-Gated Sodium Channel Nav1.7.

Molecular design, construction and analgesic mechanism insights into the novel transdermal fusion peptide ANTP-BgNPB

Targeting Neuropathic Pain: Pathobiology, Current Treatment and Peptidomimetics as a New Therapeutic Opportunity

Development of ProTx-II Analogues as Highly Selective Peptide Blockers of Nav1.7 for the Treatment of Pain

Optimizing Nav1.7-Targeted Analgesics: Revealing Off-Target Effects of Spider Venom-Derived Peptide Toxins and Engineering Strategies for Improvement

Development of Macrocyclic Neurotensin Receptor Type 2 (NTS2) Opioid-Free Analgesics

Dual Antagonism of α9α10 nAChR and GABA B Receptor-Coupled Ca V 2.2 Channels by an Analgesic αO-Conotoxin Analogue

Design, synthesis, and mechanism of action of novel μ-conotoxin KIIIA analogues for inhibition of the voltage-gated sodium channel Nav1.7

Novel therapeutics based on recombinant botulinum neurotoxins to normalize the release of transmitters and pain mediators

A Synthetic Peptide Disturbing GluN2A/SHP1 Interaction in Dorsal Root Ganglion Attenuated Pathological Pain

Sustained Relief of Ongoing Experimental Neuropathic Pain by A Crmp2 Peptide Aptamer with Low Abuse Potential

Designing Nerve Growth Factor Analogues to Suppress Pain Signal Transduction Mediated by the p75NTR-NGF-TrkA Complex: A Structural and Biophysical Perspective